First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
暂无分享，去创建一个
H. Kantarjian | G. Garcia-Manero | J. Cortes | F. Ravandi | G. Borthakur | J. Burger | J. Jorgensen | R. Champlin | S. Faderl | A. Ferrajoli | P. Kebriaei | Dan Jones | S. O'Brien | W. Wierda | R. Garris | S. Dara | D. Thomas | Rebecca E. Garris